Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063999 · ClinicalTrials.gov registry record · Phase 3
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
A Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7, sponsored by GOG Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,381
- Enrollment target
- 20
- Study locations
NCT00063999: Completed Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7, sponsored by GOG Foundation.
NCT00063999 is a Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7 that has completed, run by GOG Foundation. The registered enrollment target is 1,381 participants, above the 459-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (201% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063999, a Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7, has completed, sponsored by GOG Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,381 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has come back (recurrent). Drugs used in chemotherapy such as doxorubicin hydrochloride, cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which combination chemotherapy regimen is more effective in treating endometrial cancer.
Primary Outcome
The time alive in months from study entry to last contact or death.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Filgrastim
Study Locations (20)
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- John Muir Medical Center-Concord Campus - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente-Fremont - Fremont
- Saint Jude Medical Center - Fullerton
- Marin Cancer Care Inc - Greenbrae
- Long Beach Memorial Medical Center-Todd Cancer Institute - Long Beach
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- Clearview Cancer Institute - Huntsville
- Mobile Infirmary Medical Center - Mobile
- Providence Hospital - Mobile
Arkansas
- Highlands Oncology Group PA - Fayetteville - Fayetteville
- Washington Regional Medical Center - Fayetteville - Fayetteville
- University of Arkansas for Medical Sciences - Little Rock
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,381 participants |
| Start Date | 2003-08-25 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 3 |
What the finished NCT00063999 record still lists
NCT00063999 is an interventional study that assigns participants to a tested intervention. Its 1,381 participants enrollment target places it among the larger protocols in the corpus, above the 459-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (201% higher).
The record links to 6 conditions, with Recurrent Uterine Corpus Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT00063999 names 20 study sites across 5 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00063999 about?
NCT00063999 is a clinical study titled "Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer". This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has come back (recurrent). Drugs used i...
What is the current status of trial NCT00063999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,381 participants. The study started on 2003-08-25. Estimated completion is 2021-01-05.
What conditions does trial NCT00063999 study?
This clinical trial studies the following conditions: Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7.
What interventions are being tested in trial NCT00063999?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00063999?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00063999 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uterine Corpus Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
-
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
COMPLETED · Phase 2
-
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED
-
Prognostic Biomarkers in Patients With Endometrial Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI